platoseed
← All companies
Engage Bio logo

Engage Bio

Active

Potent, durable, and redosable non-viral genetic medicines

Winter 2022Founded 202110 peopleSan Francisco, CA, USA
Generate ideas →

About

Engage Bio has developed Tethosomes, a new class of non-viral DNA which finally unleashes potent, durable, redosable, and scalable genetic medicine. Engage’s Tethosome platform solves the two key hurdles that have held back the field of non-viral DNA: potency and toxicity. Using proven LNP technology, we deliver a therapeutic DNA and an mRNA encoding our proprietary Tethosome protein. This protein localizes DNA to the nucleus, increasing expression by over 100-fold. Critically, our Tethosome platform is invisible to immune sensors which detect foreign DNA and which can cause lethal immune reactions. This allows us to safely deliver potent DNA, re-dose when needed, and titrate expression to optimal levels.

Founders · 1

Will Olsen
Will OlsenFounder

Co-Founder & CEO of Engage Bio

HealthcareTherapeuticsSynthetic BiologyBiotechHealthcareTherapeuticsDrug discovery

Related startups

Also in Winter 2022